Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

New Discovery Will Greatly Increase The Anti-cancer Efficacy of Oncolytic Viruses

Creative Biogene
Posted on: 20 Jul 18
New Discovery Will Greatly Increase The Anti-cancer Efficacy of Oncolytic Viruses

Researchers at the Mayo Clinic have discovered that a molecular communication pathway has a great effect in the decision to treat measles virus oncolytic therapy for ovarian cancer and malignant brain tumors, while previously this pathway for tumors was considered to be defective. This finding prompted researchers to develop an algorithm that can predict the therapeutic efficacy of patients, and the relevant research results were recently published in the Journal of the National Cancer Institute.

 

‘This finding and this algorithm will help us to personalize the treatment of patients that are most suitable for the treatment of oncolytic viral therapy,’ said Dr. Evania Galanis, the correspondent author of this study, ‘We will also know which patients will benefit from combined therapy with oncology virus therapy and other immunotherapy.’

 

Until now, researchers have been arguing that there is a defect in this activated pathway in the tumor called the interferon response pathway. However, this is not the case according to the latest research results of researchers. They tested genetic mutations and signals that might reflect the efficacy of viral therapies.

 

Researchers conducted relevant experiments on human ovarian cancer and brain cancer mouse models and patients. They found that a stronger gene signal can predict treatment sensitivity and tolerability, subsequent studies also found that treatment with ruxantinib (an FDA-approved drug for the treatment of hematological malignancies) can overcome drug resistance. This drug targets the interferon response pathway and can increase the efficacy of the measles oncolytic virus therapy by 1000 times.

 

The researchers believe that these findings will help select the right patient in future clinical trials involving oncolytic viruses, meanwhile, It will change the design of this new therapy and its application in the clinic, including the development of effective combination therapies.

For more information:
www.creative-biogene.com/Product/Virus-Packaging-Kits.html

Editor's Details

Bennie George
Creative Biogene
www.creative-biogene.com
06316197922
ggllaammoorrous@gmail.com

Last updated on: 20/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.